TSX: CPH 17.46 -0.44 -2.46% Volume: 43,237 January 30, 2015
NASDAQ: CPHR 13.50 -0.99 -6.83% Volume: 8,117 January 30, 2015

Cipher Pharmaceuticals is a growing specialty pharmaceutical company that commercializes novel formulations of successful, currently marketed molecules.

Cipher's first product is a fenofibrate formulation marketed in the United States as Lipofen®. Cipher's second product, an extended-release tramadol, is marketed in the United States as ConZip® and in Canada as Durela®. Cipher's third product, a novel formulation of the acne treatment isotretinoin, was launched in the United States in Q4 2012 as Absorica™. The product was also recently launched in Canada as Epuris®.